An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Hutchmed
Hutchmed
University of California, San Diego
University of California, San Diego
American Regent, Inc.
Ohio State University Comprehensive Cancer Center
Novartis
Dana-Farber Cancer Institute
OrphAI Therapeutics
Stanford University
Gilead Sciences
Medical College of Wisconsin
University of Pennsylvania
Brown University
Karyopharm Therapeutics Inc
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
ADC Therapeutics S.A.
Fred Hutchinson Cancer Center
Gilead Sciences
Gilead Sciences
Gilead Sciences
Boehringer Ingelheim
University of California, San Diego
Hoffmann-La Roche
Dartmouth-Hitchcock Medical Center
Duke University
MedImmune LLC
Aptevo Therapeutics
Massachusetts General Hospital
Pharmacyclics LLC.